Work

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.637.637

Authors: Donald A. Bergstrom, Jason B. Clark, Alan Xiao, Matthew Griffiths, Susannah Falcon, John Pollard, Steven J. Freedman, Francis Giles

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Vertex Pharmaceuticals (United Kingdom), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2549347178

FWCI: 0.601

Cites:

Cited by: 6

Related to: 10